Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has received notification of the scheduling of a Pre-NDS meeting for the Company with the Biologics and Genetic Therapies Directorate of Health Canada on March 1, 2006. The topic of the meeting will be Generex Oral-lyn, the Company’s proprietary buccal (oral) insulin spray product (no lung deposition). The Company believes this is the first non-injectable insulin to be the subject of a Pre-NDS meeting.